Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Timing of Smoking Intervention in Alcohol Treatment (Nicotine Patch)

This study has been completed.
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Information provided by:
Minneapolis Veterans Affairs Medical Center Identifier:
First received: November 2, 1999
Last updated: February 10, 2011
Last verified: January 2008
This study will attempt to determine the best time to begin a smoking cessation program in individuals who undergo intensive treatment for alcohol dependence. The goal of this trial is to determine whether a smoking cessation program is more effective if it occurs at the same time as or after treatment for alcohol dependence. The study also will attempt to determine the effect of smoking cessation programs on the outcome of treatment for alcohol dependence.

Condition Intervention Phase
Drug: nicotine replacement patch
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Open Label
Primary Purpose: Treatment
Official Title: Timing of Smoking Intervention in Alcohol Treatment

Resource links provided by NLM:

Further study details as provided by Minneapolis Veterans Affairs Medical Center:

Estimated Enrollment: 500
Study Start Date: September 1997
Study Completion Date: January 2004
Primary Completion Date: January 2004 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   21 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Meets criteria for alcohol use disorder and other drug dependence.
  • Complete first week of alcohol treatment program.
  • Current cigarette smoker (more than 5 cigarettes/day, smoking more than 1 year).

Exclusion Criteria:

  • Lifetime diagnosis of an excluding psychiatric disorder: bipolar disorder, schizophrenia or other psychotic disorder, panic disorder with or without agoraphobia, obsessive-compulsive disorder, generalized anxiety disorder, eating disorder, post- traumatic stress disorder, antisocial personality disorder, or borderline personality disorder.
  • Unable to participate in protocol due to functional deficits or severe depression.
  • Suicidal or homicidal ideation.
  • Current use of disulfiram (Antabuse) or naltrexone (Revia).
  • Current use of pipes, cigars, or smokeless tobacco and unwillingness to stop.
  • Lives more than 100 miles from alcohol treatment facility.
  • No telephone.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00000444

United States, Minnesota
General Internal Medicine, VA Medical Center
Minneapolis, Minnesota, United States, 55417
Sponsors and Collaborators
Minneapolis Veterans Affairs Medical Center
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
  More Information Identifier: NCT00000444     History of Changes
Other Study ID Numbers: NIAAAJOS11124
R01AA011124 ( US NIH Grant/Contract Award Number )
Study First Received: November 2, 1999
Last Updated: February 10, 2011

Additional relevant MeSH terms:
Alcohol-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Ganglionic Stimulants
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Nicotinic Agonists
Cholinergic Agonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action processed this record on April 28, 2017